Carol Langford, MD, MHS

Professor of Medicine

Director of the Center for Vasculitis Care and Research

Cleveland Clinic

 

In person and via Zoom


Upon completion of this activity, participants will be able to:

  • Describe the elements used in evaluating ANCA-associated vasculitis
  • Discuss the utility of ANCA in the diagnosis of ANCA-associated vasculitis 
  • Identify the treatment options used for remission induction of ANCA-associated vasculitis 
  • Outline the treatment options to maintain remission of ANCA-associated vasculitis 

 

Disclosure of Financial Interest Summary

All planners, faculty, and others in control of educational content are required to disclose all their financial relationships with ineligible companies within the prior 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company.

Carol Langford, MD, speaker for this educational event, has received research grants from Bristol-Myers Squibb, AstraZeneca, Glaxo Smith Kline, and NS Pharma. She is also a non-paid consultant for Bristol-Myers Squibb, AbbieVie, and 
AstraZeneca.

All of the relevant financial relationships listed for these individuals have been mitigated

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include a discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.

Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Session date: 
03/27/2026 - 12:00pm EDT to 05/26/2026 - 12:59am EDT
  • 1.00 AMA PRA Category 1 Credit

    In support of improving patient care, UK HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), and the Association of Social Work Boards (ASWB) to provide continuing education for the healthcare team.

    This Live activity is designated for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

  • 1.00 Participation
    UK Healthcare CECentral certifies this activity for 1.00 hour(s) of participation.
Please login or register to take this course.
Faculty List: 
Peer reviewer(s)

Jeffrey Wolber

has no relevant financial relationships to disclose at this time.
Planner(s)

Danier Rose, PC

has no relevant financial relationships to disclose at this time.
Speaker(s)

Carol Langford, MD MHS

has a financial relationship (Grant Or Contract) with Bristol-Myers Squibb;.
has a financial relationship (Grant Or Contract) with AstraZeneca;.
has a financial relationship (Grant Or Contract) with GlaxoSmithKline;.
has a financial relationship (Grant Or Contract) with NS Pharma;.
has a financial relationship (Other) with Bristol-Myers Squibb;.
has a financial relationship (Other) with AbbVie;.
has a financial relationship (Other) with AstraZeneca;.